227935-29-7

Upstream product

• 108-86-1 bromobenzene 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 23761-26-4 3-phenyl-3-hydroxycyclobutane-1-carboxylic acid 
• 66016-28-2 3-phenylcyclobutane-1-carboxylic acid 

Downstream Products

• 56842-95-6 bicyclo<1.1.1>pentane-1,3-dicarboxylic acid 
• 83249-04-1 3-phenylbicyclo<1.1.1>pentane-1-carboxylic acid 
• 30493-96-0 methyl 3-phenylbicyclo<1.1.0>butane-1-carboxylate 
• 83249-09-6 methyl 3-phenylbicyclo<1.1.1>pentane-1-carboxylate 
• 65862-03-5 methyl 3-phenyl-2,2-dichlorobicyclo<1.1.1>pentane-1-carboxylic acid 
• 66016-28-2 3-phenylcyclobutane-1-carboxylic acid 
• 69584-48-1 1-(hydroxymethyl)-3-phenylcyclobutane 
• 36126-39-3 methyl 3-bromo-3-phenylcyclobutane-1-carboxylate 

Relevant academic research and scientific papers

ANTIDIABETIC COMPOUNDS

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Prostane derivatives

The disclosure relates to novel 15-(3-aryl- or 3-aralkyl-cyclobutyl, -cyclopentyl and -cyclohexyl)-ω-pentanor prostaglandin analogues, for example 9α,11α,15α-trihydroxy-15-(trans-3-phenylcyclobutyl)-16,17,18,19,20-pentanor-5-cis,13-trans-prostadienoic acid, to pharmaceutical or veterinary compositions containing such a compound, and to a method of inducing luteolysis in animals by orally administering such a compound.